Micromedic, which develops cancer diagnostic technologies, announced positive intermediary findings, in a clinical trial to assess its CellDetect cervical cancer technology.
Micromedic Technologies Ltd. (TASE:MCTC), which develops cancer diagnostic technologies, today announced positive intermediary findings, in a clinical trial to assess its CellDetect cervical cancer technology. The trial was conducted by its portfolio company Zetiq, which is developing a novel histo-chemical staining kit for identification of cervical neoplasia in histological and cytological urine samples.
In the clinical trial 42 urine samples were examined using Zetiq's technology and compared with biopsies or cystoscopies (if biopsies weren't taken). The results showed a 94% success rate for the technology and 88% when the method is adapted.
Micromedic's share price rose 10.48% to NIS 1.76 on the TASE in afternoon trading after the results were published.
Published by Globes [online], Israel business news - www.globes-online.com - on December 25, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012
Bio-LIght acquires 21% of Micromedic